These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 30569082)

  • 1. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engaging Stakeholders in the Design and Conduct of Embedded Pragmatic Clinical Trials for Alzheimer's Disease and Alzheimer's Disease-Related Dementias.
    Harrison J; Maslow K; Tambor E; Phillips L; Frank L; Herndon L; Epstein-Lubow G
    J Am Geriatr Soc; 2020 Jul; 68 Suppl 2(Suppl 2):S62-S67. PubMed ID: 32589275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
    Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
    Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
    Lista S; Dubois B; Hampel H
    J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
    Daviglus ML; Bell CC; Berrettini W; Bowen PE; Connolly ES; Cox NJ; Dunbar-Jacob JM; Granieri EC; Hunt G; McGarry K; Patel D; Potosky AL; Sanders-Bush E; Silberberg D; Trevisan M
    NIH Consens State Sci Statements; 2010 Apr; 27(4):1-30. PubMed ID: 20445638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerating Alzheimer's disease drug innovations from the research pipeline to patients.
    Goldman DP; Fillit H; Neumann P
    Alzheimers Dement; 2018 Jun; 14(6):833-836. PubMed ID: 29680407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.
    Hung A; Schneider M; Lopez MH; McClellan M
    J Manag Care Spec Pharm; 2020 Jul; 26(7):888-900. PubMed ID: 32584672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stakeholder perspectives on digital behavioral health applications targeting adolescent depression and suicidality: Policymaker, provider, and community insights.
    Radovic A; Kirk-Johnson A; Coren M; George-Milford B; Kolko D
    Implement Res Pract; 2022; 3():26334895221120796. PubMed ID: 37091099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
    Liu KY; Thambisetty M; Howard R
    Alzheimers Dement; 2023 Mar; 19(3):1073-1085. PubMed ID: 36161763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.
    Buckley RF; Villemagne VL; Masters CL; Ellis KA; Rowe CC; Johnson K; Sperling R; Amariglio R
    J Mol Neurosci; 2016 Nov; 60(3):354-361. PubMed ID: 27514526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development.
    Morant AV; Vestergaard HT; Lassen AB; Navikas V
    Clin Transl Sci; 2020 Jul; 13(4):652-664. PubMed ID: 32043310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care.
    Barger S; Sullivan SD; Bell-Brown A; Bott B; Ciccarella AM; Golenski J; Gorman M; Johnson J; Kreizenbeck K; Kurttila F; Mason G; Myers J; Seigel C; Wade JL; Walia G; Watabayashi K; Lyman GH; Ramsey SD
    BMC Med Res Methodol; 2019 Jun; 19(1):119. PubMed ID: 31185918
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.